TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers.
Malignant gliomas are among the rarest brain tumours, and they have the worst prognosis. Grade IV astrocytoma, known as glioblastoma multiforme (GBM), is a highly lethal disease where the standard therapies of surgery, followed by radiation and chemotherapy, cannot significantly prolong the life exp...
Main Authors: | Ivana Jovčevska, Neja Zupanec, Nina Kočevar, Daniela Cesselli, Neža Podergajs, Clara Limbaeck Stokin, Michael P Myers, Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, Helena Motaln, Maria Elisabetta Ruaro, Evgenia Bourkoula, Tamara Lah Turnšek, Radovan Komel |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4242679?pdf=render |
Similar Items
-
TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion
by: Andrej Porčnik, et al.
Published: (2021-08-01) -
Anti-Vimentin Nanobody Decreases Glioblastoma Cell Invasion In Vitro and In Vivo
by: Alja Zottel, et al.
Published: (2023-01-01) -
Sonication is a suitable method for loading nanobody into glioblastoma small extracellular vesicles
by: Sara Colja, et al.
Published: (2023-05-01) -
Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma
by: Eduardo Ruiz-López, et al.
Published: (2022-12-01) -
High <i>FREM2</i> Gene and Protein Expression Are Associated with Favorable Prognosis of <i>IDH</i>-WT Glioblastomas
by: Ivana Jovčevska, et al.
Published: (2019-07-01)